Roszymah Hamzah

Roszymah Hamzah

Auto-generated profile, based on publicly available information

Roszymah Hamzah

Hematology Department, Ampang Hospital, Ampang, Selangor, Malaysia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
RHRoszymah Hamzah
Roszymah Hamzah
DYDr Nurasyikin Yusof
Dr Nurasyikin Yusof
NTNor Rafeah Tumian
Nor Rafeah Tumian
SASuria ABDUL Abdul Aziz
Suria ABDUL Abdul Aziz
NBNur Syahida Mohammad Basri
Nur Syahida Mohammad Basri
SJSiti Afiqah Muhamad Jamil
Siti Afiqah Muhamad Jamil
Background: Immune thrombocytopenia (ITP) is well characterized in Western, European and other Asia-Pacific countries. Nevertheless, the clinical epidemiology, treatment pattern and disease outcome of ITP in Malaysia are still limited and not well known. Objective: This study aimed to describe the clinical epidemiology, treatment outcome and mortality of ITP patients in haematology tertiary multicentre in Malaysia. Methods: Clinical and laboratory data of newly diagnosed adults with ITP by a platelet count < 100 × 109/L from January 2010 to December 2020 were identified and analyzed. Results: Out of 500 incident ITP, 71.8% were females with a striking age preponderance of both genders among those aged 18– 29 years. The median age was 36 years. The median platelet count was 17.5 × 109/L, 23.0% had a secondary ITP, 34.6% had a Charlson’s score ≥ 1, 53.0% had bleeding symptoms including 2.2% intracranial bleedings (ICB). Helicobacter pylori screening was performed in < 5% of cases. Persistency and chronicity rates were 13.6% and 41.8%, respectively. Most (80.6%) were treated at diagnosis onset and 31.2% needed second-line treatment. Throughout the course of ITP, 11.0% of patients died; 3.0% and 8.0% with bleeding and non-bleeding related ITP. Conclusion: This study confirms the epidemiology of ITP is comparable with worldwide studies. Our incidence is high in the female, Malay ethnicity, primary ITP and events of cutaneous bleeding at ITP onset with 18– 29 years predominance age group for both genders. The frequency of persistent and chronic ITP is inconsistent with published literature. Corticosteroids and immunotherapies are the most prescribed first-line and second-line pharmacological treatments. Thrombopoietin receptor agonist medications (TPO-RAs) usage is restricted and splenectomy is uncommon. Our mortality rate is similar but ITP related bleeding death is fourth-fold lower than previous studies. Mortality risks of our ITP patients include age ≥ 60 years, male, severe bleeding at presentation, CCI≥ 1 and secondary ITP.

10 August 2023 in eJHaem
Verified
Journal Article
Open access
EEEzalia Esa
Ezalia Esa
AMAhmad Sabry Mohamad
Ahmad Sabry Mohamad
RHRoszymah Hamzah
Roszymah Hamzah
FHFaidatul Syazlin Abdul Hamid
Faidatul Syazlin Abdul Hamid
NANur Aisyah Aziz
Nur Aisyah Aziz
NYNorafiza Mohd Yasin
Norafiza Mohd Yasin
Haemoglobin (Hb) G-Makassar is a rare Hb variant. It presents a diagnostic challenge as it imitates sickle Hb (Hb S) in standard electrophoresis and high-performance liquid chromatography assays requiring DNA analysis to confirm diagnosis. Both have point mutations in codon 6, exon 1 in the beta-globin (HBB) gene with different pathogenicities. This study describes the clinical phenotype, haematology and genotype of Hb G-Makassar. Clinical and laboratory data of 38 cases of Hb G-Makassar over 8 years were analysed. Hb G-Makassar was confirmed by a direct sequencing of HBB gene and co-inheritance of alpha-thalassaemia determined through multiplex gap-PCR and multiplex Amplification Refractory Mutation System polymerase chain reaction. All cases were Malays, predominantly from Terengganu (n = 20, 52.6%). There were 14 (36.8%) males and 24 (63.2%) females with median age of 25 years. Majority (n = 33, 86.8%) had features of thalassaemia trait with mean +/- SD for Hb, mean cell volume (MCV) and mean cell haemoglobin (MCH) as 13.21 g/dL +/- 1.69, 73.06 +/- 4.48 fL and 24.71 +/- 1.82 pg, respectively. None had evidence of haemolysis or thromboembolic complications. Six genotypes were identified; ssG-Makassar/ss,alpha alpha/alpha alpha (n = 19, 50.0%), ssG-Makassar/ssE,alpha alpha/alpha alpha (n = 4, 10.5%), ssG-Makassar/ssNewYork,alpha alpha/alpha alpha (n = 1, 2.6%), ssG-Makassar/ss,alpha alpha/-alpha (n = 11, 28.9%), ssG-Makassar/ss,alpha alpha/alpha Adana alpha (n = 2, 5.3%) and ssG-Makassar/ss,alpha alpha/-SEA (n = 1, 2.6%). The ssG-Makassar/ss,alpha alpha/alpha alpha showed that features of thalassaemia trait with mean +/- SD for Hb, MCV and MCH were 13.74 g/dL +/- 2.40, 76.18 +/- 6.02 fL and 25.79 +/- 2.41 pg, respectively. This is the largest study reporting a significant number of Hb G-Makassar in Malaysia. Although the mutation is similar to Hb S, the phenotype is benign. image

1 December 2021 in Herba Polonica
Verified
Journal Article
Open access
PDF file
AMAhmad Sabry Mohamad
Ahmad Sabry Mohamad
MNMuhammad Noor Nordin
Muhammad Noor Nordin
IAIsmail Che Ani
Ismail Che Ani
JJJohan Jemberang
Johan Jemberang
RIReezal Ishak
Reezal Ishak
RHRoszymah Hamzah
Roszymah Hamzah
Summary: Introduction: Volten VR4® capsules containing herb extract of Kaempferia parviflora has been claimed to reduce blood glucose in patients with diabetes. Objectives: This preliminary study is conducted to evaluate the efficacy of Volten VR4® on healthy individuals and type-2 diabetes mellitus volunteers. The extracts of 400 mg capsules of Kaempferia parviflora (KP) were used to measure the blood glucose level of 2-hour postprandial. Methods: The healthy group consists of 15 young adults aged 20-30 with no history of serious diseases, while the diabetic group includes 12 individuals aged 35-75 diagnosed with type-2 diabetes mellitus. Data were validated through the Willcoxon and Friedman test statistics and error distribution. The investigation was continued to trace the capsules contents of elements using inductively coupled plasma optical emission spectrometry (ICP-OES) techniques. Results: It has been shown that KP reducing blood sugar levels has been associated with flavonoids and methoxyflavones components. The result specifically showed that consuming VR4® capsules can significantly reduce blood glucose, either at the state of fasting or postprandially. In the study the content of mineral and heavy metal elements in VR4® capsules has been evaluated. Conclusion: Volten VR4® Kaempferia parviflora extract is safe to be consumed at a single dose of 400 mg. The study also has shown that the participants are free from adverse reactions and hypoglycaemia.

1 May 2024 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
RHRoszymah Hamzah
Roszymah Hamzah
AMAhmad Sabry Mohamad
Ahmad Sabry Mohamad
NYNorafiza Mohd Yasin
Norafiza Mohd Yasin
EEEzalia Esa
Ezalia Esa
GCGuo Chen
Guo Chen
VSVeena Selvaratnam
Veena Selvaratnam
Background: Human hemoglobin of G-Makassar and hemoglobin E (Hb E) are hemoglobin variants that affect Beta (β) globin. Hb G-Makassar is a very rare variant while Hb E is estimated to affect at least one million people worldwide. Both Hb G-Makassar and Hb E can be inherited in the heterozygous, homozygous or compound heterozygous state. This case series describes the characteristics of four individuals with compound heterozygosity for Hb G-Makassar/Hb E cases in Malaysia. To the best of our knowledge, these are the only four individuals with this genotype reported in the literature. Case Series: We present four cases of compound heterozygosity for Hb G-Makassar/Hb E identified from October 2014 to January 2021. All the cases were incidental findings whereby the screening Hb analysis showed the presence of peaks in both Hb S and Hb E zones on capillary electrophoresis (CE) and cation-exchange high-performance liquid chromatography (HPLC). Molecular analysis confirmed the findings of compound heterozygous Hb G-Makassar/Hb E. Two cases had a history of anemia secondary to unrelated conditions that resolved with treatment of the underlying cause. The other two cases were asymptomatic individuals who were detected through Malaysia’s National Thalassemia Screening program. On the last follow-up, all the individuals were well, non-transfusion dependent, and had no reported history of chronic anemia, bleeding, hemolysis or thromboembolism complications. Conclusion: The cases reported here highlight the possibilities for rare compound heterozygous states in multi-ethnicity populations such as Malaysia. Compound heterozygous Hb G-Makassar/Hb E individuals are clinically silent with laboratory values suggesting microcytic and hypochromic red blood cells. Further local epidemiology or population studies with genotyping tests are required for a better understanding of the diversity of its clinical phenotype.